Efficacy is not everything, access is The medical advances here are real and profound but Dr Kovil reminded, The same medicine can mean very different things to your wallet, depending on where you live. Clinical breakthroughs only translate into population health gains when systems including insurers, governments, manufacturers and regulators, make access practical and sustainable
Coverage may be possible only if prescribed for OSA
GLP-1s in 2025: Usage, Coverage, and Costs The rise of GLP-1 medications has transformed diabetes and obesity management
Staying on semaglutide is the conservative choice
Individual factors such as metabolic rate, body weight, and age may theoretically influence how B12 is distributed and utilised, though evidence for their impact on injection intervals is limited
It also states most patients resolve the problem within two to four weeks of making those changes without interrupting treatment